Engagement of CD160 receptor by HLA-C is a triggering mechanism used by circulating natural killer (NK) cells to mediate cytotoxicity - PubMed (original) (raw)
. 2002 Dec 24;99(26):16963-8.
doi: 10.1073/pnas.012681099. Epub 2002 Dec 16.
Aliz Barakonyi, Jérome Giustiniani, Françoise Lenfant, Anne Marie-Cardine, Maryse Aguerre-Girr, Magali Rabot, Ivan Hilgert, Fathia Mami-Chouaib, Julie Tabiasco, Laurence Boumsell, Armand Bensussan
Affiliations
- PMID: 12486241
- PMCID: PMC139252
- DOI: 10.1073/pnas.012681099
Engagement of CD160 receptor by HLA-C is a triggering mechanism used by circulating natural killer (NK) cells to mediate cytotoxicity
Philippe Le Bouteiller et al. Proc Natl Acad Sci U S A. 2002.
Abstract
Circulating human natural killer (NK) lymphocytes have been functionally defined by their ability to exert cytotoxic activity against MHC class I-negative target cell lines, including K562. Therefore, it was proposed that NK cells recognized the "missing self." We show here that the Ig-like CD160 receptor expressed by circulating CD56(dim+) NK cells or IL-2-deprived NK cell lines is mainly involved in their cytotoxic activity against K562 target cells. Further, we report that HLA-C molecules that are constitutively expressed by K562 trigger NK cell lysis through CD160 receptor engagement. In addition, we demonstrate, with recombinant soluble HLA-Cw3 and CD160 proteins, direct interaction of these molecules. We also find that CD158b inhibitory receptors partially interfere with CD160-mediated cytotoxicity, whereas CD94CD159a and CD85j have no effect on engagement with their respective ligands. Thus, CD160HLA-C interaction constitutes a unique pathway to trigger NK cell cytotoxic activity.
Figures
Fig 1.
Activation of fresh peripheral blood NK cell-mediated cytolysis by CD160. (A) Cytotoxic activity of freshly isolated human PB-NK separated in CD160+ and -160− populations against K562 target cell in the absence of mAb (no mAb) or in the presence of mAb CL1-R2 (CD160). (B) Cytotoxic activity of PB-NK either untreated (CD160bright+) or cultured for 3 days with IL-2 (CD160dim+) against K562 target cell in the absence of mAb (no mAb) or in the presence of mAb CL1-R2 or Ig-isotype control (IgG1). (C) CD160 expression in fresh PB-NK cells either untreated (−IL-2) or cultured for 3 days with IL-2 (+IL-2) was analyzed by flow cytometry using FITC-labeled BY55 mAb. Data are representative of several independent experiments. Open profile is Ig-isotype control staining. (D) Redirected lysis assay of P815 using fresh human CD160+ PB-NK in the presence of mAbs specific for the indicated molecules or control IgG1. The effector-to-target cell (E:T) ratio used was 25. Results of A, B, and D are mean ± SD of triplicates and are representative of three independent experiments.
Fig 2.
CD160 engagement triggers cytolytic activity in NKL, NK92, and NK3.3 cell lines. Shown is the cytotoxicity of NKL, NK92, and NK3.3 effector cells cultured without IL-2 against K562 in the absence of mAb (no mAb) or in the presence of mAb CL1-R2 (CD160) or control IgG1. Results are mean ± SD of triplicates and are representative of three independent experiments.
Fig 3.
Engagement of CD160 by HLA-C, constitutively expressed by K562, triggers NK cell cytotoxicity. (A) K562 cells were analyzed by flow cytometry for surface expression of HLA class I using broad anti-HLA-class I (mAb W6/32), anti-HLA-C (mAb B1.23.2), anti-HLA-C free heavy chains (mAb L31), anti-HLA-E (mAb MEM-E/06), or anti-HLA-G (mAb 87G) (black profiles) followed by PE-labeled conjugate. Open profiles are Ig-isotype control stainings. Data are representative of several independent experiments. (B) Cytotoxicity of NK92 cultured without IL-2 against K562 in the absence of mAb (no mAb) or in the presence of mAb MEM-E/06 (HLA-E, 5 μg/ml), mAb B1.23.2 (HLA-C, 10 μg/ml), or Ig-isotype control (IgG). Results are mean ± SD of triplicates and are representative of several independent experiments.
Fig 4.
Soluble recombinant HLA-Cw3 and CD160 proteins bind to JAR-Cw3 and Jurkat-CD160, respectively. (A Upper) By flow cytometry, mAb CL1-R2 stained Jurkat-CD160 but not Jurkat cells (black profiles). Open profiles are Ig-isotype control stainings. (A Lower) flow cytometry binding of soluble HLA-Cw3 cross-linked with B1.23.2 mAb, followed by incubation with PE-streptavidin on Jurkat-CD160 and NK.3.3 cells but not Jurkat (black profiles). Open profiles are control staining with B1.23.2 mAb and streptavidin-PE. (B) Flow cytometry showing binding of mAb B1.23.2 on JAR-Cw3 but not JAR (Upper, open profiles are Ig-isotype control staining), and of soluble CD160-Flag, after incubation with anti-Flag mAb followed by PE-labeled conjugate on Jurkat-CD160 and NK.3.3 cells but not Jurkat (Lower, open profiles are staining after incubation with control Jurkat supernatant). (C) Cytotoxicity of NK92 cultured without IL-2 against JAR-Cw3 target cells in the absence of mAb (no mAb) or in the presence of mAb CL1-R2 (CD160). Results are mean ± SD of triplicates and are representative of three independent experiments.
Fig 5.
CD160-induced NK92 cytotoxicity is not blocked by inhibitory receptors specific for HLA-E and -G, whereas HLA-C, through its interaction with CD158b, alters CD160-induced NK3.3 cytotoxicity. (A) Surface expression of HLA class I on K562-G transfectants was monitored with W6/32 (broad HLA class I), B1.23.2 (HLA-C), L31 (free HLA-C heavy chains), MEM-E/06 (HLA-E), or 87G (HLA-G) mAbs (black profiles). Open profiles are Ig-isotype control stainings. Data are representative of several independent experiments. (B) Cytotoxicity of NK92 cultured without IL-2 against K562-G target cells, either in the absence of mAb (no mAb) or in the presence of isotype control (IgG), mAb B1.23.2 (HLA-C), mAb 87G (HLA-G), or mAb MEM-E/06 (HLA-E). The effector-to-target cell (E:T) ratio was 10. Results are mean ± SD of triplicates and are representative of several independent experiments. (C) Redirected lysis assay of P815, using NK92 cells in the presence of anti-CD160 or -CD59 mAbs mixed with anti-CD159a or -CD85j mAb or with control IgG. The E:T ratio used was 25. Results are mean ± SD of triplicates and are representative of three independent experiments. (D) Cytotoxicity of NK3.3 cultured without IL-2 against K562 in the absence of mAb (no mAb) or in the presence of mAb B1.23.2 (HLA-C), or (E) mAb CL1-R2 (CD160), anti-CD158b (CD158b) mAb, or anti-CD158b together with anti-CD160 (CD160/CD158b) mAbs. Results are mean ± SD of triplicates and are representative of three independent experiments.
Similar articles
- Trophoblast cell line resistance to NK lysis mainly involves an HLA class I-independent mechanism.
Avril T, Jarousseau AC, Watier H, Boucraut J, Le Bouteiller P, Bardos P, Thibault G. Avril T, et al. J Immunol. 1999 May 15;162(10):5902-9. J Immunol. 1999. PMID: 10229826 - Cutting edge: engagement of CD160 by its HLA-C physiological ligand triggers a unique cytokine profile secretion in the cytotoxic peripheral blood NK cell subset.
Barakonyi A, Rabot M, Marie-Cardine A, Aguerre-Girr M, Polgar B, Schiavon V, Bensussan A, Le Bouteiller P. Barakonyi A, et al. J Immunol. 2004 Nov 1;173(9):5349-54. doi: 10.4049/jimmunol.173.9.5349. J Immunol. 2004. PMID: 15494480 - The natural killer cell-mediated killing of autologous dendritic cells is confined to a cell subset expressing CD94/NKG2A, but lacking inhibitory killer Ig-like receptors.
Della Chiesa M, Vitale M, Carlomagno S, Ferlazzo G, Moretta L, Moretta A. Della Chiesa M, et al. Eur J Immunol. 2003 Jun;33(6):1657-66. doi: 10.1002/eji.200323986. Eur J Immunol. 2003. PMID: 12778484 - Natural killer cell-mediated recognition of human trophoblast.
Biassoni R, Bottino C, Millo R, Moretta L, Moretta A. Biassoni R, et al. Semin Cancer Biol. 1999 Feb;9(1):13-8. doi: 10.1006/scbi.1998.0108. Semin Cancer Biol. 1999. PMID: 10092546 Review. - CD160: a unique activating NK cell receptor.
Le Bouteiller P, Tabiasco J, Polgar B, Kozma N, Giustiniani J, Siewiera J, Berrebi A, Aguerre-Girr M, Bensussan A, Jabrane-Ferrat N. Le Bouteiller P, et al. Immunol Lett. 2011 Aug 30;138(2):93-6. doi: 10.1016/j.imlet.2011.02.003. Epub 2011 Feb 13. Immunol Lett. 2011. PMID: 21324341 Review.
Cited by
- Identification of CD160-TM as a tumor target on triple negative breast cancers: possible therapeutic applications.
Scheffges C, Devy J, Giustiniani J, Francois S, Cartier L, Merrouche Y, Foussat A, Potteaux S, Bensussan A, Marie-Cardine A. Scheffges C, et al. Breast Cancer Res. 2024 Feb 15;26(1):28. doi: 10.1186/s13058-024-01785-x. Breast Cancer Res. 2024. PMID: 38360636 Free PMC article. - γδ T cells mediate robust anti-HIV functions during antiretroviral therapy regardless of immune checkpoint expression.
Field KR, Wragg KM, Kent SJ, Lee WS, Juno JA. Field KR, et al. Clin Transl Immunology. 2024 Jan 29;13(2):e1486. doi: 10.1002/cti2.1486. eCollection 2024. Clin Transl Immunology. 2024. PMID: 38299190 Free PMC article. - Beyond the anti-PD-1/PD-L1 era: promising role of the BTLA/HVEM axis as a future target for cancer immunotherapy.
Sordo-Bahamonde C, Lorenzo-Herrero S, Granda-Díaz R, Martínez-Pérez A, Aguilar-García C, Rodrigo JP, García-Pedrero JM, Gonzalez S. Sordo-Bahamonde C, et al. Mol Cancer. 2023 Aug 30;22(1):142. doi: 10.1186/s12943-023-01845-4. Mol Cancer. 2023. PMID: 37649037 Free PMC article. Review. - Natural Killer Cell Engagers (NKCEs): a new frontier in cancer immunotherapy.
Zhang M, Lam KP, Xu S. Zhang M, et al. Front Immunol. 2023 Aug 9;14:1207276. doi: 10.3389/fimmu.2023.1207276. eCollection 2023. Front Immunol. 2023. PMID: 37638058 Free PMC article. Review. - Plasma extracellular vesicle transcriptomics identifies CD160 for predicting immunochemotherapy efficacy in lung cancer.
Liao J, Lai H, Liu C, Zhang X, Ou Q, Li Q, Li Y, Wang Z, Liu C, Wu X, Wang H, Yu H, Sun S, Zhao X, Hu Z, Zhang Y, Lin Y, Yu B, Huang S, Wang J. Liao J, et al. Cancer Sci. 2023 Jul;114(7):2774-2786. doi: 10.1111/cas.15804. Epub 2023 Apr 20. Cancer Sci. 2023. PMID: 37014183 Free PMC article.
References
- Lanier L. L., Le, A. M., Civin, C. I., Loken, M. R. & Phillips, J. H. (1986) J. Immunol. 136, 4480-4486. - PubMed
- Moretta A., Bottino, C., Mingari, M. C., Biassoni, R. & Moretta, L. (2002) Nat. Immunol. 3, 6-8. - PubMed
- Borrego F., Kabat, J., Kim, D. K., Lieto, L., Maasho, K., Pena, J., Solana, R. & Coligan, J. E. (2002) Mol. Immunol. 38, 637-660. - PubMed
- Lanier L. L. (2001) Nat. Immunol. 2, 23-27. - PubMed
- Cerwenka A. & Lanier, L. L. (2001) Immunol. Rev. 181, 158-169. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials